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Abstract
Introduction High values of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are related with poor
prognosis in patients with gastric cancer. However, this association has been rarely assessed in Hispanic populations that show
important clinicopathological differences to Asian and Caucasian patients. In this study, we determined the prognostic value of
these biomarkers in Hispanic patients from Costa Rica.
Materials and Methods We retrieved data regarding pre-treatment NLR and PLR, as well as clinical variables from medical
records of 381 consecutive gastric cancer patients treated in four major hospitals in Costa Rica between 2009 and 2012.
Univariate and multiple Cox regression analyses were performed to assess the value of NLR and PLR as predictors of overall
survival (OS) and disease-free survival (DFS). The best cutoff point was based on the maximization of the Log-rank test.
Results Median follow-up was 13.21 months. In univariate analysis, a NLR ≥ 5 was associated with reduced DFS (hazard ratio
(HR) 2.31; 95% confidence interval (CI) 1.78–3.00; p < 0.001) and poor OS (HR 2.24; 95% CI 1.72–2.92; p < 0.001). Similarly,
a PLR ≥ 350 was associated with worse DFS (HR 2.28; 95%CI 1.70–3.06; p < 0.001) and poor OS (HR 2.33; 95%CI 1.73–3.13;
p < 0.001). After adjustment for potential confounders, multivariate analysis revealed that only the NLR ≥ 5 was independently
associated with worse DFS (HR 1.97; 95% CI 1.44–2.47) and OS (HR 1.59; 95%CI 1.15–2.28).
Conclusions NLR ≥ 5 was independently associated with worse OS and DFS in Hispanic patients with gastric cancer.
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Introduction
Gastric cancer represents the fifth most common form of
cancer and the third cause of cancer-related death in both
sexes worldwide [1]. Almost 70% of cases occur in de-
veloping countries, particularly in Eastern Asia, Central
and Eastern Europe, and Central and South America. In
these regions, stomach cancer is the third most frequently
diagnosed malignancy among men and the fifth cause of
incidence among women [2]. In 2015, stomach cancer
was the second cause of cancer-related mortality in both
sexes among Costa Rican patients [3]. This in line with
the mortality rates reported in other Central and South
American countries, which are among the highest in the
world [4, 5]. Despite the high prevalence and mortality of
this disease in Hispanic countries, patients from this re-
gion are usually under-represented in clinical trials, and
few data are available regarding prognostic factors for
overall survival (OS) and disease-free survival (DFS).
Previous studies have shown a different clinicopathologic
behavior of this malignancy among Hispanic patients [6, 7]
that may be partly related to their genetic background. These
studies have shown that gastric adenocarcinoma in Hispanic
populations are more likely to affect young patients with
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diffuse and undifferentiated tumors of distal location [6, 7].
Other reports have consistently revealed shorter overall sur-
vival and poorer long-term clinical outcomes in Hispanic pa-
tients than in White-non-Hispanic populations [8, 9].
The neutrophil-lymphocyte ratio (NLR) and the platelet-
lymphocyte ratio (PLR) have been recently identified as prog-
nostic factors in patients with solid tumors, including gastric
cancer [10, 11]. However, the prognostic role of these bio-
markers in patients with gastric adenocarcinoma from
Hispanic origin is largely unknown. Given the fairly distinc-
tive outcomes and clinical characteristics of this malignancy
in this population, we performed the present study to deter-
mine the prognostic value of the NLR and PLR as predictors
of OS and DFS in patients with gastric cancer from a Hispanic
background (Costa Rica), and to establish the best cutoff value
to adequately classify patients according to their baseline risk.
Methods
The clinical records of all consecutive patients diagnosed
with gastric adenocarcinoma from January 2009 to
January 2012 in four major public hospitals of Costa
Rica (Caja Costarricense de Seguro Social) were retro-
spectively reviewed. Baseline clinical and tumor charac-
teristics were manually retrieved from the clinical records.
The NLR (defined as the absolute neutrophil count divid-
ed by the absolute lymphocyte count) and PLR (defined
as the absolute platelet count divided by the absolute lym-
phocyte count) were calculated from full blood test per-
formed prior surgery or chemotherapy. Patients with he-
matological disorders, corticosteroids, or any kind of
acute or chronicle inflammatory diseases were excluded,
as well as patients with no pre-treatment blood tests. All
cases were classified according to the TNM criteria as
described by 7th Edition of the American Joint Committee on
Cancer. Patients with non-metastatic gastric cancer underwent a
surgical procedure that consisted of total or subtotal gastrectomy
with lymph node dissection (D1 or D2) depending on tumor
location and surgeon’s preference.
Patients could receive adjuvant treatment, either chemo-
therapy or chemoradiotherapy (CRT), according to the medi-
cal oncologist consultation. In case of metastatic disease and
good performance status (ECOG 0 to 2), patients received
cytotoxic therapy.
Patients were followed up at least at 3-month intervals dur-
ing the first 2 years, then at 6-month intervals for 3 years, and
yearly thereafter. Follow-up included a computer tomography
scan and esophagogastroduodenoscopic examination as clini-
cally indicated.
The primary outcome of this study was OS as defined from
the date of first cancer treatment to the date of death according
to the Costa Rican National Registry. DFS was defined from
the date of primary surgery to the date of clinically confirmed
recurrence or death. Recurrence was defined as the presence
of a biopsy-proven tumor with adenocarcinoma features or the
presence of imaging highly suspicious of tumor recurrence.
Statistical Analysis
Categorical variables are presented as percentages and contin-
uous variables as means and standard deviations (SD).
The best NLR and PLR cutoff points were determined
based on the maximization of the log-likelihood ratio method
as proposed by Contal and O’Quigley [12].
The chi-square test or Fisher’s exact test were used for
comparison of frequencies, while the Student’s t test was used
for comparison of quantitative variables. An OS and DFS
analysis was performed using the Kaplan-Meier method.
The Log-rank test was used to compare survival curves.
Univariate and multiple COX regression analyses were used
to calculate the crude and adjusted hazard ratios (HR) with
their 95% confidence interval (95% CI). Variables with a p
value less than 0.10 by univariate analysis were included in
the multivariate analysis using the backward stepwise tech-
nique. An interaction term (NLR*PLR) was added to the
model to test for the interactive effect of NLR and PLR.
A p value of less than 0.05 was considered statistically
significant. Statistical analysis was carried out using SPSS
version 21.0 for Mac (Chicago, Illinois, USA). All statistical
tests were two-tailed.
Results
A total of 381 patients met the inclusion criteria. Table 1
summarizes the main characteristics of the included pa-
tients and compares baseline characteristics according to
the NLR and PLR. After statistical analysis, the optimal
cutoff was set at 5 for NLR (corresponding to a log-rank
value of 37.15) and 350 for PLR (corresponding to a log-
rank value of 33.32). Median NLR and PLR were 2.61
and 180.72, respectively. Patients allocated to the high
NLR and PLR groups were more likely to have an ad-
vanced clinical stage, poor performance status, and did
receive less chemotherapy or surgery in comparison with
patients with low NLR and PLR values.
Median follow-up time was 13.21 months (range 0–
84 months). During this period, a total of 273 patients
(71.7%) died. Overall, 5-year survival probability was
27.1% (95% CI 22.61–31.62). Figure 1 shows the OS
probability according to NLR and PLR categories.
Median survival time was 5.0 months (95% CI 1.58–
8.42) for patients with NLR ≥ 5 and 18.2 months (95%CI
12.10–24.32) for patients with NLR less than 5 (HR 2.24;
95% CI 1.72–2.92, Log-rank test: p < 0.001). Similarly,
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median survival time was 5.57 months (3.46–7.68) for pa-
tients with PLR ≥ 350 and 17.07 months (95% CI 11.74–
22.40) for patients with PLR less than 350 (HR 2.33; 95%
CI 1.73–3.13, Log-rank test: p < 0.001).
Figure 2 shows the DFS probability of patients according to
NLR and PLR categories. Events of recurrence or progression
were more frequently observed in the high NLR and high PLR
groups. Median DFS was 3.5 months (95% CI 0.70–6.30) in
patients with NLR ≥ 5 and 15.43 months (95% CI 10.05–20.81)
in patients with NLR lower than 5 (HR 2.31; 95% CI 1.78–3.00,
Log-rank test:p< 0.001).Likewise,medianDFSwas4.67months
(95% CI 2.97–6.37) for patients with PLR ≥ 350 versus
14.73 months (95% CI 9.56–19-89) for patients with PLR less
than 350 (HR 2.28; 95% CI 1.70–3.06, Log-rank test: p< 0.001).
The results of the univariate and multiple COX regression
analyses for OS and DFS are presented in Tables 2 and 3,
respectively. After adjustment for potential confounders, the
NLR ≥ 5 was independently associated with worse OS and
Table 1 General characteristics of the included population
Variables All patients (N = 381) Neutrophil-lymphocyte ratio p value Platelet-lymphocyte ratio p value
< 5 (n = 292) ≥ 5 (n = 89) < 350 (n = 319) ≥ 350 (n = 62)
Sex (%) 0.32 0.07*
Male 218 (57.2) 163 (55.8) 55 (61.8) 176 (55.2) 42 (67.7)
Female 63 (42.8) 129 (44.2) 34 (38.2) 143 (44.8) 20 (32.3)
Age (mean, standard deviation) 61.2 ± 14.6 60.4 ± 14.3 63.9 ± 15.2 0.045* 61.1 ± 14.6 61.6 ± 14.7 0.84
Tumor location(%) 0.35 0.28
Antropylorus 85 (22.3) 60 (20.5) 25 (28.1) 71 (22.2) 14 (22.6)
Gastric body 215 (56.4) 168 (57.5) 47 (52.8) 176 (55.2) 39 (62.9)
Fundus 72 (18.9) 58 (19.9) 14 (15.7) 65 (20.4) 7 (11.3)
Not reported 9 (2.4) 6 (2.1) 3 (3.4) 7 (2.2) 2 (3.2)
Tumor differentiation (%) 0.87 0.97
Well 67 (17.6) 54 (18.5) 13 (14.6) 57 (17.9) 10 (16.1)
Moderated 76 (19.9) 56 (19.2) 20 (22.5) 65 (20.4) 11 (17.8)
Poor 117 (30.7) 89 (30.5) 28 (31.5) 99 (31.0) 18 (29.1)
Undifferentiated 55 (14.4) 44 (15.1) 11 (18.6) 45 (14.1) 10 (16.1)
Unknown 66 (17.3) 49 (16.7) 17 (28.1) 53 (16.6) 13 (20.9)
Lauren classification (%) 0.79 0.28
Intestinal 222 (58.2) 172 (58.9) 50 (56.2) 192 (60.2) 29 (46.8)
Diffuse 159 (41.8) 120 (41.1) 39 (43.8) 127 (39.8) 33 (53.2)
TNM stage (%) 0.006* 0.002*
I 10 (2.6) 8 (2.7) 2 (2.2) 9 (2.8) 1 (1.6)
II 100 (26.3) 81 (27.7) 19 (21.3) 89 (27.9) 11 (17.7)
III 133 (34.9) 112 (38.6) 21 (23.6) 119 (37.3) 14 (22.6)
IV 123 (32.3) 82 (28.0) 41 (46.1) 91 (28.5) 32 (51.6)
Unknown 15 (3.9) 9 (3.0) 6 (6.7) 11 (3.5) 4 (6.5)
ECOG (%) 0.031* 0.021*
0 100 (26.2) 71 (24.3) 29 (32.6) 84 (26.3) 16 (25.8)
1 217 (57.0) 179 (61.3) 38 (42.7) 189 (59.2) 28 (45.2)
2 35 (9.2) 23 (7.9) 12 (13.5) 27 (8.5) 8 (12.9)
3 21 (5.5) 13 (4.5) 8 (9.0) 15 (4.7) 6 (9.7)
4 8 (2.1) 6 (2.1) 2 (2.2) 4 (1.3) 4 (6.5)
Surgery (%) 0.006* 0.01*
Yes 213 (55.9) 174 (59.6) 39 (43.8) 187 (58.6) 26 (41.9)
No 168 (44.1) 118 (40.4) 50 (56.2) 132 (41.4) 36 (58.1)
Chemotherapy (%) 0.001* 0.036*
Yes 206 (54.1) 172 (58.9) 34 (38.2) 180 (56.4) 26 (41.9)
No 175 (45.9) 120 (41.1) 55 (61.8) 139 (43.6) 36 (58.1)
*Statistically significant at p < 0.05
J Gastrointest Canc
DFS. Also, TNM stage, ECOG performance status, and the
absence of chemotherapy or surgery were associated with
poor outcomes. The multivariate analyses did not reveal any
statistically significant interaction between the NLR and the
PLR (Tables 2 and 3).
Discussion
Inflammatory cells play an essential role in the pathogenesis
and progression of cancer and are important determinants of
patient’s clinical outcome [13]. Neutrophils are thought to
promote carcinogenesis by favoring angiogenesis, metastasis,
and cell proliferation [14]. Cytotoxic lymphocytes are respon-
sible of clearing tumor cells through recognition of tumor-
specific antigens or tumor-associated antigens [13, 15].
Additionally, platelets adhere to tumor cells and facilitate their
metastasis from the blood stream [16]. Therefore, the combi-
nation of increased number of circulating neutrophils, plate-
lets, and lymphocytopenia could explain the poor outcomes of
patients with high NLR and PLR.
In this study, we show that both the NLR and the PLR are
prognostic factors in Hispanic gastric cancer patients from
Costa Rica, a country with high incidence and mortality for
this malignancy [3]. After covariate adjustment, only the NLR
was independently associated with worse OS and DFS. Our
findings are in accordance with previous reports in patients
with solid tumors, including gastric cancer [11, 17–20].
Moreover, the majority of these studies assessing the role of
NLR and PLR as prognostic biomarkers have been conducted
in Asian populations, and almost no data from Latin-American
countries are available. Recently, it has been determined that
patients from Hispanic background tend to have poorer out-
comes than Asian and White-non-Hispanic populations [8, 9].
We consider therefore that our results make an important con-
tribution by evaluating the prognostic value of novel biological
parameters in a geographical region where gastric adenocarci-
noma represents a leading cause of death due to cancer [3–5].
Not all trials evaluating the prognostic usefulness of NLR
and PLR in solid tumors come to the same conclusion andmuch
of the heterogeneity found probably derives from different cut-
off points used in each study. For example, in a recent meta-
analysis of 33,432 patients with solid tumors [18], a range of
cutoff values from 1.9 to 7.2was associatedwith poor outcomes.
In the present analysis, we decided to calculate the optimal NLR
and PLR threshold based on the sequential approach suggested
byContal andO’Quigley [12]. A similar statistical methodology
has been previously used by other authors [20] and it is preferred
Fig. 2 Disease-free survival
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over ROC curves,median values, or interquartile ranges because
of its ability to control for multiple variables and time-to-event
outcomes. Nevertheless, as other authors suggest, we must con-
sider the NLR and PLR as continuous variables with increasing
risk increments [21].
Although patients with high NLR were older, had more
advanced disease, lower performance status and received
more treatment (surgery or chemotherapy) than patients in
the low NLR category, the multivariate analysis for OS
and DFS showed that this index was not altered by these
confounding variables. This implies that the NLR is a
strong predictor for long-term outcomes and its incorpo-
ration into predictive nomograms is warranted, as recently
showed by Choi and colleagues [22].
Gastric cancer prognosis is usually determined by patho-
logical variables that are available after a surgical procedure or
Table 2 Univariate and
multivariate Cox regression
analysis for overall survival
Variable Crude hazard ratio
(95% confidence interval)







< 60 years 1.0 1.0
≥ 60 years 1.27 (0.99–1.61) 1.11 (0.85–1.45)
Tumor differentiation 0.001* 0.25
Well 1.0 1.0
Well moderated 1.26 (1.10–1.43) 1.06 (0.96–1.17)
Poor 2.52 (2.20–2.86) 2.12 (1.92–2.34)




TNM stage < 0.001* < 0.001*
I 1.0 1.0
II 1.80 (1.54–2.10) 1.44 (1.23–1.70)
III 3.60 (3.08–4.20) 2.88 (2.46–3.40)
IV 5.40 (4.62–6.30) 4.32 (3.69–5.10)
ECOG < 0.001* 0.004*
0 1.0 1.0
1 1.36 (1.17–1.59) 1.24 (1.07–1.44)
2 2.72 (2.34–3.18) 2.48 (2.14–2.88)
3 4.08 (3.51–4.77) 3.72 (3.21–4.32)
4 5.44 (4.68–6.36) 4.96 (4.28–5.76)
Surgery < 0.001* < 0.001*
No 1.0 1.0
Yes 0.27 (0.21–0.35) 0.31 (0.24–0.41)
Chemotherapy 0.014* < 0.001*
No 1.0 1.0
Yes 0.74 (0.58–0.94) 0.57 (0.44–0.75)
NLR < 0.001* 0.005*
< 5 1.0 1.0
≥ 5 2.24 (1.72–2.92) 1.59 (1.15–2-28)
PLR < 0.001* 0.079*
< 350 1.0 1.0
≥ 350 2.33 (1.73–3.13) 1.39 (0.96–2.00)
NLR*PLR 1.0 0.51
**Statistically significant at p < 0.10
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during disease staging. Conversely, the NLR and PLR can be
easily calculated from hemogram results that are available in
different settings with limited resources. Having inexpensive
but reliable prognostic factors is particularly important in the
context of gastric cancer since almost two-thirds of cases oc-
cur in developing countries [1, 2]. The identification and val-
idation of these sensitive biomarkers may help identify pa-
tients who may receive a different therapy and follow-up.
Our study has some limitations due to its retrospective de-
sign. However, it validates previous findings regarding the
prognostic value of circulating neutrophils, platelets, and lym-
phocytes in patients with gastric cancer.
In conclusion, our findings show that the NLR is an
independent prognostic factor for OS and DFS in
Hispanic patients with gastric cancer regardless of their
clinical stage, performance status, and treatment received.
Table 3 Univariate and
multivariate Cox regression
analysis for disease-free survival
Variable Crude hazard ratio
(95% confidence interval)







< 60 years 1.0 1.0
≥ 60 years 1.24 (0.98–1.58) 1.17 (0.90–1.52)
Tumor differentiation 0.002* 0.25
Well 1.0 1.0
Moderated 1.22 (1.07–1.39) 1.06 (0.96–1.17)
Poor 2.44 (2.14–2.78) 2.12 (1.92–2.34)




TNM stage < 0.001* < 0.001*
I 1.0 1.0
II 1.82 (1.56–2.13) 1.47 (1.26–1.72)
III 3.64 (3.12–4.26) 2.94 (2.52–3.54)
IV 5.46 (4.68–6.39) 3.41 (3.78–5.16)
ECOG < 0.001* 0.009*
0 1.0 1.0
1 1.34 (1.15–1.55) 1.22 (1.05–1.41)
2 2.68 (2.30–3.10) 2.44 (2.10–2.82)
3 3.92 (3.45–4.65) 3.66 (3.15–4.23)
4 5.36 (4.60–6.20) 4.88 (4.20–5.64)
Surgery < 0.001* < 0.001*
No 1.0 1.0
Yes 0.28 (0.22–0.36) 0.32 (0.25–0.42)
Chemotherapy 0.055* 0.006*
No 1.0 1.0
Yes 0.79 (0.63–1.00) 0.69 (0.53–0.89)
NLR < 0.001* 0.001*
< 5 1.0 1.0
≥ 5 2.31 (1.78–3.00) 1.97 (1.44–2-47)
PLR < 0.001* 0.24
< 350 1.0 1.0
≥ 350 2.28 (1.70–3.06) 1.13 (0.78–1.64)
NLR*PLR 1.0 0.64
*Statistically significant at p < 0.10
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Further studies, however, should prospectively explore the
prognostic value of these biomarkers in order to incorpo-
rate them into usual clinical practice.
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